Results 221 to 230 of about 2,601,708 (287)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Transcription factor switching drives subtype-specific pancreatic cancer. [PDF]

Nat Genet
Rao SV, Young L, Cheeseman D, Flynn S, Krebs N, Couturier DL, Mack S, Brais R, Temple J, Smith A, Papachristou E, Pelicano C, Chilamakuri CSR, Herka K, Baba H, Farah L, Cheung PF, Siveke J, Guerrier S, Insolia L, Gill M, Archer Goode E, Kupczak S, Cheng Y, Borsari G, Jodrell D, D'Santos C, Russell A, Grünwald BT, Serrao E, Chernukhin I, Carroll JS.   +31 more
europepmc   +1 more source

Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors [PDF]

, 1995
Carlos Suñé, Mariano A. García-Blanco
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Correction: Promotion of BST2 expression by the transcription factor IRF6 affects the progression of endometriosis. [PDF]

Front Immunol
Li J, He Y, Qu Y, Ren C, Wang X, Cheng Y, Sun L, Zhang X, Zhang G.   +8 more
europepmc   +1 more source

Transcription Factor Interactions Mediate EGF-Dependent COX-2 Expression

, 2013
Kaiming Xu, Hui‐Kuo G. Shu
openalex   +1 more source

Scoring functions for transcription factor binding site prediction [PDF]

, 2005
Markus Friberg, Peter von Rohr, Gastón H. Gonnet   +2 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

A short SUMOylation tag modulates transcription factor activity. [PDF]

J Biol Chem
Bouchard AY, Vivet AJI, Cabana VC, Li C, Thibault P, Lussier MP, Mader S, Cappadocia L.   +7 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source